Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
tc
biotechnology
bio
emerging technologies
jennifer doudna
molecular biology
non-coding rna
repetitive dna sequences
american biochemists
berkeley college of chemistry faculty
biology
crystallographers
editas medicine
harvard university alumni
health
howard hughes medical investigators
living people
members of the united states national academy of sciences
university of california
yale department of molecular biophysics & biochemistry faculty
1963 births
american women scientists
applied genetics
bioethics
biological engineering
broad institute
engineering disciplines
enzymes
gene delivery
genetic engineering
life extension
medical genetics
medical research
members of the national academy of medicine
women biochemists
$250 million
1987 establishments in texas
23andme
3d printing
What
crispr
9
×
read
9
×
editing
gene
cas
doudna
jennifer
institute
technology
berkeley
berkeley’s
inventor
patent
today
biotech
broad
called
charpentier
colleague
discovery
emmanuelle
future
genes
genetic
max
month
public
rights
stage
years
ability
academy
actually
advances
afternoon
ambitious
andme
anniversary
applications
argument
Language
Current search:
crispr
×
read
×
@techcrunch.com
7 years ago
CRISPR pioneer Jennifer Doudna shines hope on the future of genetic modification at SXSW
@techcrunch.com
7 years ago
Crunch Report | Judge Rules CRISPR-Cas9 Belongs to Broad Institute
@techcrunch.com
7 years ago
CRISPR-Cas9 inventor Jennifer Doudna’s plans on moving forward, genetically modifying humans
@theverge.com
7 years ago
Gene editing will transform cancer treatment
@techcrunch.com
7 years ago
Oral arguments for who owns CRISPR-Cas9 starts next month
@techcrunch.com
7 years ago
CRISPR will have to wait for that Nobel prize
@techcrunch.com
7 years ago
Jennifer Doudna, inventor of gene editing technology CRISPR Cas9, is coming to Disrupt
@techcrunch.com
8 years ago
Innovation in genomics and the future of medtech
@techcrunch.com
8 years ago
Editas biotech stock drops by 26% over CRISPR patent dispute